PET/CT and PET/MRI, the world's leading-edge imaging screening devices, have extremely significant advantages in the early screening and diagnosis of a wide range of benign and malignant tumours throughout the body, the nervous system and the cardiovascular system, and can detect tumours as small as millimetres, especially useful for the early detection and treatment of liver cancer, breast cancer and pancreatic cancer. Translated with www.DeepL.com/Translator (free version)
Apparatus
-
-
The global ADC drug market will be approximately $5.2 billion by 2021
-
Carvykti gains new ground and competes with its "predecessor"!
-
Recently, Nassim Annabi, an assistant professor of Northeastern University in the United States, and other researchers from the University of Sydney in Australia jointly developed an advanced surgical glue MeTro. When using, the glue directly enters the wound and is solidified and sealed within 60 seconds. Naxim said, "The advantage of MeTro formula is that once it touches the organ, it will appear as gel instantly and will not slip."
-
As more and more organisms become resistant to antibiotics, the threat to human health is increasing. The overuse of antibiotics leads to drug resistance. It is very important to limit the use of antibiotics. The research team of the University of Alberta in Canada has recently developed a hand-held detection instrument, which allows first-line clinicians to distinguish between patients with viral infection or bacterial infection within a few minutes, thus helping to reduce unnecessary antibiotic prescriptions and overuse of antibiotics. Because antibiotics are only effective for bacteria, if the patient is infected with virus, there is no need to prescribe antibiotics.
-
The Fraunhofer Institute in Germany has now developed two techniques that could make testing faster and cheaper.
-
The "me better" strategy has always been a great story for pharmaceutical companies.
-
Apparatus
"New 'Breakthrough' Alzheimer's Drug Approved: Slows Brain Decline By 27%, But $26,500/Year Pricing Controversial
Eisai and Biogen have partnered to develop Leqembi and have priced it at $26,500 per year.
-
Apparatus
Georgia Institute of Technology 3D printing heart valve model to improve the success rate of valve replacement
It is reported that researchers from Georgia Institute of Technology and Piemonte Heart Institute are using customized 3D printed heart valve models based on patients' heart CT scanning to improve the success rate of transcatheter aortic valve replacement (TAVR) surgery. Their aim is to avoid perivalvular leakage. This research has been published in JACC: Cardiovascular Imaging.
-
Apparatus
FDA Grants Orphan Drug Status To Two New Therapies In a Row, And These Two Groups Of Patients Are Expected To Benefit!
Recently, the US FDA has granted orphan drug status to two new therapeutics in a row. One is a small molecule inhibitor, PCLX-001, for the treatment of acute myeloid leukaemia; the other is a T-cell therapy, ET140203, for the treatment of hepatoblastoma. Both therapies are currently in relevant trials.